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ABSTRACT
MicroRNAs (miRNA) are a class of small RNA mol-
ecules that regulate numerous critical cellular
processes and bind to partially complementary se-
quences resulting in down-regulation of their target
genes. Due to the incomplete homology of the
miRNA to its target site identification of miRNA
target genes is difficult and currently based on com-
putational algorithms predicting large numbers of
potential targets for a given miRNA. To enable the
identification of biologically relevant miRNA targets,
we describe a novel functional assay based on a
30-UTR-enriched library and a positive/negative se-
lection strategy. As proof of principle we have used
mir-130a and its validated target MAFB to test this
strategy. Identification of MAFB and five additional
targets and their subsequent confirmation as
mir-130a targets by western blot analysis and
knockdown experiments validates this strategy for
the functional identification of miRNA targets.
INTRODUCTION
MicroRNAs (miRNA) regulate key biological events in
both normal and cancer cells [reviewed in (1,2)]. Human
miRNAs act mainly by inhibiting target mRNA transla-
tion and to a lesser extent by promoting the degradation
of the target mRNA [reviewed in (3,4)]. To obtain insight
into the function of miRNAs, considerable effort has gone
into writing different computational algorithms that
identify miRNA targets (5). However, a major drawback
of these prediction models is a substantial false positive
rate and an inevitable bias due to reliance on the few
known miRNA/target mRNA interactions (6).
Furthermore, the available algorithms are based on
several parameters of which homology between the
50-seed sequence of the miRNA and a complementary
region in the 30-UTR of the target mRNA is an important
component. However, perfectly matched miRNA seeds
are neither necessary nor sufﬁcient for all functional
miRNA-target interactions. Data obtained by immuno-
precipitation of miRNA containing ribonucleoprotein
complexes have shown that only 30–45% of the recovered
miRNAs contain perfectly matched seed sequences corres-
ponding to the 30-UTR (7,8). Furthermore, the genetically
validated targets for let-7 in Caenorhabditis elegans such as
lin-41, pha-4 and let-60 contain wobbles or bulges in the
seed region (9). Recently it has been shown that mir-24
regulates several genes by binding to seedless 30-UTR
miRNA recognition elements and that mir-146a regulates
murine STAT1 in the absence of canonical target seed
sequences (10,11).
The lack of sensitivity and speciﬁcity of the developed
computational algorithms is clearly shown by the fact that
for the 1048 human miRNAs identiﬁed (miRBase release
16 September 2010), experimentally validated targets
have only been reported for 206 miRNAs (miRecords at
http://mirecords.umn.edu/miRecords/). Therefore, the
vast majority of conﬁrmed miRNAs lack even a single
validated target. Hence, there is a clear need for
methodologies that identify and validate the functional
targets of speciﬁc miRNAs. Here, we describe a novel,
selection-based functional assay for the identiﬁcation of
miRNA targets. This strategy makes no assumptions
based on previously identiﬁed sequences, but relies
directly on down-regulation, by a miRNA, of a selectable
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quences. Cells that either do not express or express low
levels of the miRNA of interest are transfected with a
30-UTR library inserted downstream of a TKzeo fusion
gene in the plasmid p30TKzeo. Zeocin selection results in
a population of cells that express the TKzeo fusion protein
and are resistant to zeocin and sensitive to Ganciclovir
(GCV). The zeocin-resistant cells are next transfected
with the miRNA of interest cloned into a selectable
expression vector and transduced cells are isolated.
Subsequent GCV treatment selects for cells that have
down-regulated the TKzeo fusion protein expression
either by inhibition of translation or mRNA cleavage.
The 30-UTR sequences present downstream of the
TKzeo fusion gene were isolated from the GCV resistant
cells by PCR ampliﬁcation and identiﬁed by sequencing.
Using mir-130a as a model, we were able to isolate ﬁve
target genes and validated these by western blot and mir
knockdown experiments. The procedure was further
validated through identiﬁcation of targets for mir-10a.
MATERIALS AND METHODS
Plasmids and library construction
Plasmid p30TKzeo was constructed by digestion of
psectag2 (Invitrogen) with NheI, ﬁlling-in and DraIII di-
gestion which left the vector backbone with the CMV
promoter and the SV40 polyA. TKzeo was removed as
an NcoI, ﬁlled-in SalI fragment from plasmid pUT102
(Cayla, France). Vector and insert were ligated in a
3-way ligation with a linker that introduced 2 SﬁI sites
(underlined) that differ in their interpalindromic
sequence enabling directional cloning of inserts with the
same SﬁI sites.
TCGAGGCCATTAAGGCCGGCCGCCTCGGCCCA
CTTC
Plasmid p30TKzeo was veriﬁed by Sanger sequencing,
digested with SﬁI and gel cleaned.
A cDNA library derived from oligo dT primed total
RNA from human brain directionally cloned into the
same SﬁI sites as above in the mammalian expression
vector pEXP1 was obtained (Clontech). The brain
cDNA library was digested with SﬁI and cDNAs
<2.5Kb were isolated. The cDNA was gel puriﬁed and
ligated into SﬁI-digested p30TKzeo vector. The ligation
mixture was electroporated into pre-aliquoted E-Shot
DH10B T1 electrocompetent Escherichia coli
(Invitrogen), according to the manufacturer’s protocol.
A total of 600000 individual clones were expanded as
single colonies on 20 square 400cm
2 plates. The bacterial
colonies were scraped off the plates, pooled, expanded and
plasmid DNA was isolated (Qiagen Giga prep).
Mir-130a was cloned by PCR ampliﬁcation of a 974-bp
fragment from human genomic DNA containing
the mir-130a pre-miRNA hairpin with the following
primers: forward CGGATCCTTGAGGCCTAGAGCT
CTGCT, reverse TGAATTCGCAGATGGCATCAAAA
introducing BamHI and EcoRI restriction sites. The
PCR fragment was TOPO-TA cloned (Invitrogen) and
sequenced. Correct plasmid DNA was digested with
BamHI and EcoRI and cloned into the retroviral vector
pBabepuro.
Mir-10a was cloned similarly as a 998-bp fragment with
the following primers: forward TGGATCCTCACAAAC
TAAAGGCTTGGAG and reverse TGAATTCCAATAA
CACTCCTTGGTAATCG.
Part of the MAFB 30-UTR containing the mir-130a
targetsite was cloned from human genomic DNA by
PCR ampliﬁcation with the following forward and
reverse primers: GGCCATTAAGGCCGCCTGCGCTA
ATTGTAGGA GGCCGAGGCGGCCCTCGTTTCTG
ATGCAGGACA.
These primers introduce SﬁI sites for directional cloning
into p30TKzeo. The PCR product was TOPO-TA cloned
sequenced and cloned into p30TKzeo.
Transfection and selection
The plasmid library (100mg/ﬂask) was transfected using
the BES co-precipitation procedure into 10
8 MCF7 cells,
in 24 triple layer ﬂasks (NUNC) (4 10
6 cells per ﬂask).
Forty-eight hours post-transfection the cells were selected,
for 10 days, in 500mg/ml zeocin. The cells were
trypsinized, pooled and expanded in the presence of
500mg/ml zeocin. Of this mixed population (1.6 10
7
cells) were plated in four triple layer ﬂasks and transfected
with either pBabepuro or pBabepuro expressing mir-130a
and selected in 1mg/ml puromycin for 48h.
Cells were then seeded at a density of 10
6 in 10-cm
dishes and selected with 8mM clinical grade GCV
(Roche) for 10 days. Pooled populations of GCV
selected cells containing mir-130a were expanded in the
presence of 8mM GCV and 1mg/ml puromycin.
Genomic DNA was isolated (Qiagen DNAeasy kit) from
the GCV selected cells and the inserts ampliﬁed by PCR
with p30TKzeo speciﬁc primers ﬂanking the cloning site
(Forward AACTGCGTGCACTTCGTG and Reverse A
AGGCGATTAAGTTGGGTAA), cloned into the
TopoTA vector and sequenced using M13F and M13R
sequencing primers. Similarly, 8 10
6 zeocin-resistant
MCF7 cells were transfected with pBabepuro-mir-10a
and treated as above.
ABI solid next-generation sequencing
To analyse the complexity of the library of zeocin-resistant
MCF7 cells inserts were PCR ampliﬁed with the above
primers. The PCR product was fragmented to an
average length of 150bp and ends repaired as per ABI
Solid protocols. Adapters were then ligated to the
library DNA containing sequences necessary for ABI
solid sequencing. Ligation products of  200bp were
then fractionated by acrylamide gel electrophoresis and
PCR ampliﬁed according to ABI protocols using
primers speciﬁc for the ligated adapter. Sequencing was
performed on an ABI SOLiD
tm v3 system with a read
length of 35bp. Number of reads was 8233395.
Western blot analysis
Cells were lysed in RIPA buffer (Sigma) freshly supple-
mented with protease inhibitor cocktail (Sigma) on ice
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(Sigma) and 10% b-mercaptoethanol was added. Samples
were boiled for 5min before gel loading. Proteins were
separated on 10% SDS–polyacrylamide gels, then
transferred to nitrocellulose membranes (GE Healthcare)
and blocked with 5% non-fat dry milk for 1h at room
temperature. Immunoblotting was performed with the fol-
lowing primary antibodies: TPT1 (ab58362, mouse mono-
clonal IgG, 1:1000; Abcam), CYP27A1 (ab64889, rabbit
polyclonal IgG 1:1000, Abcam), MAFB (ab56242, rabbit
polyclonal IgG 1:2000, Abcam) and KIFAP3
(12700-1-AP, rabbit polyclonal IgG 1:1500; ProteinTech
Group, Cambridge, UK). The membrane was washed
with 3  TBS-0.05% Tween-20 buffer and incubated
with a horseradish peroxidase-conjugated secondary
antibody against the host IgG. Subsequently, the blot
was developed using an enhanced chemiluminescent
(ECL plus) detection system (GE Healthcare, UK) and
exposed to ECL ﬁlm (GE Healthcare, UK). The blot
was stripped with ReBlot plus strong antibody stripping
buffer (Millepore, UK) and re-probed with a g-tubulin
antibody (sc31787, goat polyclonal IgG 1:500; Santa
Cruz Biotech) for loading control.
QRT–PCR
Total RNA was isolated using Tri-reagent (Invitrogen)
and quantiﬁed by absorbance at 260nm. Gene-speciﬁc
primers for mir-10a, mir-130a and RUN6B (All from
Applied Biosystems) were used to generate cDNA from
5 ng of RNA using the TaqMan miRNA Reverse
Transcription Kit (Applied Biosystems). QPCR was per-
formed on this product using the Taqman Universal
Mastermix-No UNG (Applied Biosystem) according to
the manufacturer’s protocol in an ABI 7900 HT
Sequence Detection System. The delta Ct (relative expres-
sion) was calculated after normalizing the target to
RNU6B.
Mir-130a knockdown
The mir-130a knockdown experiments were performed by
the reverse transfection procedure according to the manu-
facturer’s instructions, with Lipofectamine RNAiMAX
(Invitrogen).
MCF-7 and NIH/3T3 cells cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM PAA) supplemented
with 10% Foetal bovine serum (PAA), 1  penicillin/
streptomycin/glutamine (Sigma), 1mM Pyruvate
(Sigma). Prior to addition to the test wells, cells were
transferred to fully supplemented media without
antibiotics.
In six-well plates, 500ml of DMEM medium containing
Glutamine and Pyruvate, but no foetal calf serum or anti-
biotics was added to the wells, followed by 3.75ml (25nM
ﬁnal) of MIRIDIAN hairpin mir-130a inhibitors or
control inhibitor (Dharmacon) to the appropriate wells
followed by 5ml of Lipofectamine RNAiMAX. The result-
ant mixture was incubated at room temperature for
15min. After incubation, 3 10
5 cells in 2.5ml of fully
supplemented DMEM media without antibiotics were
added to each well. All conditions were setup in duplicate.
Control conditions of cells only (without any additives)
and cells +5ml of Lipofectamine RNAiMAX, were also
included in the experimental design. Cultures were
incubated in humidiﬁed CO2 incubator at 37 C for 48h
after which protein extracts were prepared for western blot
analysis.
RESULTS
Library cloning and transfection
Cells that do not express the miRNA of interest are trans-
fected with a library of genes cloned downstream of a
TKzeo fusion gene that provides resistance to zeocin
and sensitivity to GCV (see Figure 1 for a schematic
representation of the target identiﬁcation strategy).
3’UTR Library Transfection
Zeocin selection 
microRNA e.g., mir-130a 
transfection and selection mir-130a target
TK Zeo 3’UTRs
Ganciclovir selection
PCR and Sequencing 
non mir-130a target
Figure 1. Schematic representation of the functional assay for miRNA target discovery.
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(i.e. the target cell library). The subsequent introduction of
the miRNA of interest into the target cell library results in
the down-regulation of TKzeo in cells containing a cDNA
with a target site for the introduced miRNA abrogating
the zeocin resistance but by the same token gaining resist-
ance to GCV due to reduced expression of TKzeo.
To generate a cDNA library with the largest number of
individual genes present, we cloned a brain cDNA library
downstream of a TKzeo fusion gene. Brain and testis are
the two tissues expressing the largest number of genes (12).
cDNA was removed from a commercially available, Oligo
dT primed, brain cDNA library and directionally cloned
downstream of TKzeo in the plasmid p30TKzeo
(Supplementary Figure S1). Individual bacterial colonies
(600000) were expanded. Analysis of 72 individual clones
conﬁrmed the presence of different length cDNA in all 72
clones tested (results not shown). As proof of concept, we
used mir-130a and mir-10a which have veriﬁed targets in
the transcription factor MAFB (v-maf musculo-
aponeurotic ﬁbrosarcoma oncogene homolog B) and
HoxA1 (13) and spiked the 30-UTR library with 10% of
p30TKzeo with a MAFB 30-UTR. This library was trans-
fected into MCF7 cells, which express very low levels of
mir-130a and mir-10a, (Supplementary Figure S2) and
selected in 500mg/ml zeocin. This resulted in a library of
approximately 40000 independent MCF7 clones. PCR
ampliﬁcation and Next-generation sequencing of the
inserts present in these clones resulted in 9873 unique
hits representing 5626 different genes present in the
library of approximately 40000 MCF7 clones of which
5207 were protein coding genes and 419 were derived
from non-coding mRNAs (see Supplementary Data).
GCV sensitivity
Initially three constructs of a selectable marker fused
in-frame to HSVTk were tested for resistance to the se-
lectable marker and sensitivity to GCV. The constructs
used were HyTK, TKpuro and TKzeo conferring resist-
ance to hygromycin, puromycin and zeocin respectively.
TKzeo conferred the highest sensitivity to GCV and
was therefore selected for the library construction
(Supplementary Figure S3). To analyse the GCV sensitiv-
ity of the zeocin-resistant cells normal MCF7 cells and
zeocin-resistant cells were plated and incubated with dif-
ferent concentrations of GCV. After 10 days the plates
were stained, clearly showing that untransduced MCF7
cells are resistant to GCV up to the highest concentration,
24mM, tested (Figure 2). In contrast, zeocin resistant
MCF7 cells were sensitive to GCV even at the lowest con-
centration, 2mM, tested. Conversely, it was shown that
down-regulation of TKzeo by binding of mir-130a to the
MAFB UTR cloned downstream of TKzeo resulted in
zeocin sensitivity of these MCF7 cells (Supplementary
Figure S4). To test the stability of the sensitivity to
GCV over time of the zeocin-resistant MCF7 cells,
zeocin was removed at Day 0 and at Days 1, 30 and 60
after zeocin removal cells were selected in 8mM GCV for
10 days. The results show that in cells that had been
without zeocin selection pressure for 30 or 60 days false
positive GCV-resistant clones appear. However, in cells
that have only been without zeocin for 1 day no
GCV-resistant colonies develop. Renewed zeocin selection
at Day 60 for 10 days followed by GCV selection restored
GCV sensitivity to the cells (Supplementary Figure S5).
miRNA target identiﬁcation
Zeocin-resistant MCF7 cells were transfected with
pBabepuro-mir-130a and after 48h selected in 1mg/ml
puromycin resulting in approximately 10000 individual
MCF7 clones. As control zeocin-resistant MCF7 cells
were transfected with empty vector pBabepuro. After
96h 8mM GCV was added and cells were selected for
10 days in both puromycin and GCV which resulted in
GCV-resistant clones in mir-130a transfected cells but not
in control pBabepuro transfected cells (Figure 3).
Genomic DNA was isolated from the GCV-resistant
cells, PCR ampliﬁed, TOPO-TA cloned and 96 of the re-
sulting bacterial clones were sequenced. Of these 96
clones, 70 contained a MAFB insert. In addition, we
identiﬁed TPT1 (tumour protein translationally controlled
1) in 3 clones, PRR14 (proline rich 14) in 3, KIFAP3
(kinesin-associated protein 3) in 3, MITD1 (microtubule
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Figure 2. MCF7 cells were transfected with the plasmid library and
selected in 500mg/ml zeocin. Zeocin resistant and normal MCF7 cells
were selected in different concentrations of GCV showing GCV sensi-
tivity of the library transfected cells.
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CYP27A1 (cytochrome P450 family 27 subfamily A poly-
peptide 1) in 2. The remainder of the tested clones had no
insert in the Topo TA vector (Table 1). To further validate
the procedure an identical small scale experiment was per-
formed to identify targets for mir-10a, sequencing of 24
bacterial clones identiﬁed 4 putative targets, STMN2
(Stathmin like 2) in 9 clones, KATNA1 (Katanin p60) in
4, and CRMP1 (Collapsin response mediator protein 1)
in 3. A further three clones contained HoxA1 (Homeobox
A1) a validated target for mir-10a (13) (Table 1).
Expression of both mature mir-130a and mir-10a in the
transfected cells was measured by QRT–PCR 48h after
transfection and after puromycin selection
(Supplementary Figure S6).
Target validation
To validate the putative mir-130a targets, western blot
analysis of endogenous protein expression was per-
formed in MCF7 cells transfected with the empty vector
pBabepuro or pBabepuro-mir-130a. Protein extracts
obtained from MCF7 cells were probed with antibodies
to TPT1 (Abcam), KIFAP3 (PTG Cambridge) and
CYP27A1 (Abcam). MCF7 cells do not express en-
dogenous MAFB, therefore, HepG2 cells (which do
express MAFB) were transfected with pBabepuro or
pBabepuro-mir-130a and protein extract was used to
probe for MAFB (Santa Cruz). Blots were stripped and
re-probed with a g-tubulin antibody (Santa Cruz). There
were no commercial antibodies available for PRR14 and
MITD1. The results showed clear down-regulation of
MAFB, TPT1, KIFAP3 and CYP27A1 (Figure 4A–D).
To determine whether these proteins were also regulated
at the mRNA level, we analysed total RNA from the cell
lines by QRT–PCR and found no difference in the levels
of mRNA for MAFB and the novel mir-130a targets
identiﬁed in this study, indicating that mir-130a modulates
expression of these proteins at the translational level
(Figure 4E).
Of the putative novel targets for mir-130a the highest
level of down-regulation ( 80%, Figure 4B) was observed
for TPT1. TPT1 plays a role in many cellular processes
such as cell cycle progression, apoptosis and carcinogen-
esis (14). TPT1 expression is highly regulated both at the
transcriptional and translational level and is ubiquitously
expressed in most tissues, however TPT1 expression is low
in brain (15), from which the 30-UTR library was derived,
indicating the robustness of this selection procedure.
To further investigate TPT1 as a target for mir-130a,
MCF7 cells expressing exogenous mir-130a were trans-
fected with two MIRIDIAN hairpin inhibitors directed
ABC MCF7 + Library 
+ 8µM GCV
MCF7 + Library + pBabePuro
+ 8µM GCV
MCF7 + Library + mir-130a
+ 8µM GCV
Figure 3. GCV selection of library transfected cells with or without mir-130a. Cells (10
6 MCF7 cells) transfected with p30TKzeo+library (A)o r
MCF7 cells transfected with p30TKzeo+library+pBabepuro empty vector (B) or transfected with p30TKzeo+library+pBabepuro-mir-130a (C) were
plated in 10-cm plates and selected in 8mM GCV. After 10 days plates were stained with Coomassie blue.
Table 1. Identity and frequency of targets isolated for mir-10a and mir-130a
mir-130a mir-10a
Accession number Name Number
of clones
Accession number Name Number
of clones
NM_005461.3 MAFB 70 NM_001199214.1 STMN2 9
NM_003295.2 TPT1 3 NM_007044.3 KATNA1 4
NM_024031.2 PRR14 3 NM_001014809.1 CRMP1 3
NM_014970.3 KIFAP3 3 NM_005522.4 HoxA1 3
NM_138798.1 MITD1 2
NM_000784.3 CYP27A1 2
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(Dharmacon). Cells were transfected using RNAiMAX
transfection reagent (Invitrogen) and after 48h analysed
for protein expression. Western blot analysis
demonstrated a 3- to 4-fold up-regulation of TPT1 expres-
sion in MCF7-mir-130a cells when treated with the hairpin
inhibitors but not in cells treated with the control hairpin
inhibitor or mock transfected cells (Figure 5A). Similarly
NIH/3T3 cells, which express high levels of endogenous
mir-130a (Supplementary Figure S2), were treated with
the MIRIDIAN hairpin inhibitors. Western blot analysis
48h after transfection showed a 3- to 4-fold up-regulation
of TPT1 protein in these cells, validating TPT1 as a target
for mir-130a (Figure 5B). Western blot analysis of the
same NIH/3T3 protein extracts showed that the inhibition
of mir-130a also resulted in the up-regulation of two other
identiﬁed targets KIFAP3 and CYP27A1, although to a
lesser extent, 2- and 0.4-fold, respectively (Supplementary
Figure S7).
DISCUSSION
To our knowledge, this study represents the ﬁrst func-
tional assay for the identiﬁcation of miRNA target
genes. This highly efﬁcient assay does not merely rely on
homology or binding to a putative target but on func-
tional activity. Furthermore, this procedure will identify
targets that are down-regulated either by mRNA degrad-
ation or inhibition of translation and also miRNA targets
that are regulated by binding to ‘seedless’ recognition
elements (10). Due to the nature of the assay, it will
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Figure 4. Western blot and QRT–PCR analysis of identiﬁed mir-130a targets. Endogenous protein expression levels were determined in
untransfected, empty vector (pBabepuro) and mir-130a transfected cells (pBabepuro-mir-130a). Cells were transduced using the BES precipitation
procedure. (A) HepG2 cell extract probed with MAFB antibody (Santa Cruz) showing down-regulation of MAFB in mir-130a expressing cells. (B–D)
MCF7 cells probed with TPT1 antibody (Abcam), CYP27A1 antibody (Abcam) and KIFAP3 antibody (PTG Cambridge). Expression of the
respective proteins was down-regulated in the presence of mir-130a. Blots were stripped and re-probed with a g-tubulin antibody (Santa Cruz) as
a loading control. Expression levels were quantiﬁed by densitometry as shown in the corresponding bar graphs. (E) Determination of mRNA levels
by QRT–PCR. To investigate whether the down-regulation of mir-130a targets was due to mRNA degradation or inhibition of translation, the
mRNA levels of MAFB, TPT1, CYP27A1 and KIFAP3 were quantiﬁed by QRT–PCR in triplicate on untransfected cells (UN), empty vector
(pBabepuro) transfected cells (C) and pBabepuro-mir130a transfected cells (130a). The results show that mRNA levels remain unchanged indicating
that the protein knockdown is due to inhibition of translation.
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extent and are therefore likely to be amongst the most
important targets of the miRNA under investigation. It
is therefore likely that even in a large scale experiment the
number of targets identiﬁed by this assay will be consid-
erably smaller than predicted by computational algo-
rithms, expression array or Ago2-IP procedures which
identify hundreds of putative targets (8,16,17). Similarly
the SILAC method results in the identiﬁcation of
hundreds of putative targets (18). This ﬁrst SILAC
based study for the identiﬁcation of miRNA targets
ﬁnds relatively mild repression of approximately 300
proteins after miRNA transfection in fairly small groups
of 3000–3500 proteins. Furthermore, of the approximately
300 proteins identiﬁed only 60% contained a seed
sequence for the miRNA under investigation (18).
This assay relies on the down-regulation of expression
of a fusion construct by a miRNA resulting in the conver-
sion of GCV resistance to GCV sensitivity of cells.
Therefore, it is important to use a fusion construct
conferring the highest sensitivity to GCV. We tested
three different fusion constructs and found that TKzeo
resulted in the highest sensitivity to low concentrations
of GCV.
Furthermore, the miRNA of interest should not be ex-
pressed highly in the test cells. We examined a number of
cell lines for expression of mir-130a and mir-10a, by
QRT–PCR, and found that the breast epithelial carcin-
oma cell line MCF7, which grows as an adherent mono-
layer, showed one of the lowest levels of mir-130a and
mir-10a expression. Expression was also low in Jurkat
and HL60 cells which are suspension cells. Adherent
cells can be transfected with higher efﬁciency and there-
fore MCF7 cells were used to construct the target cell
library. Expression proﬁling of MCF7 has shown that
these cells only express 25% of the proﬁled miRNAs
(19) and accordingly the established library of approxi-
mately 40000 independent MCF7 clones expressing 5626
different cDNAs could be used to identify targets for
many more miRNAs.
In addition to the validation of MAFB as a mir-130a
target, this strategy identiﬁed a further ﬁve putative
targets for mir-130a. Western blot analysis of endogenous
protein levels for four of the identiﬁed targets
demonstrated down-regulation of all these targets by
mir-130a and similarly the knockdown of mir-130a in
NIH/3T3 cells resulted in up-regulation of TPT1,
KIFAP3 and CYP27A1.
At present, there are ﬁve experimentally validated
mir-130a targets TAC1 (20), CSF1 (21), MEOX2 (22),
HoxA5 (22) and MAFB (13). Of these validated targets
we only isolated MAFB with this procedure. However
next-generation sequencing showed that none of the add-
itional validated mir-130a targets were present in the 5626
cDNAs comprising the starting library of approximately
40000 clones.
A small-scale repeat experiment was performed to
identiﬁed targets for mir-10a using the same library
spiked with 10% MAFB. Sequencing 24 clones identiﬁed
four targets (Table 1) for mir-10a one of which is HoxA1 a
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Figure 5. Inhibition of mir-130a expression by MIRIDIAN hairpin inhibitors. (A) MCF7-mir-130a cells were either mock transfected (mir130aL) or
transfected with MIRIDIAN hairpin inhibitors (Dharmacon). Cells were transfected with control hairpin inhibitor (mir130C), or two hairpin
inhibitors (mir130a1, mir130a2) directed against mir-130a. After 48h protein extracts were prepared and western blot analysis with anti-TPT1
was performed. Knockdown of mir-130a restores the TPT1 expression to  80–90% of the control MCF7 expression. (B) NIH/3T3 cells, which
express high levels of mir-130a, were treated the same as MCF7 cells above. Knockdown of endogenous mir-130a results in a 3- to 4-fold
up-regulation of TPT1 protein.
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as a mir-130a target (13). Importantly in this experiment
we did not isolate MAFB as a false positive target for
mir-10a although the library had been spiked with 10%
MAFB.
We also investigated the stability of GCV sensitivity of
the zeocin-resistant cells and found that a number of false
positives appear over time in cultures that are not under
selection pressure of zeocin. This is probably due to
silencing of the CMV promoter which drives expression
of the Tkzeo fusion gene resulting in GCV resistance due
to the absence of HSV thymidinekinase expression.
However, zeocin selection restores the GCV sensitivity
and it is therefore important to select the cells with
zeocin prior to miRNA introduction.
These ﬁndings show the ﬁdelity and also the obvious
limitations of this strategy; that is, it does identify
miRNA targets that are present in the library but it
cannot ﬁnd targets that are absent from the target cell
library. To overcome these limitations, a novel normalized
cDNA library has been constructed in the p30TKzeo
vector (Sigma). This library contains cDNA derived
from the ‘Human Universal Reference Total RNA’
(Clontech), which is a mixture of RNA derived from
several human tissues, and cDNA derived from the
‘Universal Human Reference RNA’ (Agilent) which is a
mixture of RNA from 10 human cell lines.
Next-generation sequencing of this novel library showed
the presence of 16923 unique genes which is  77% of the
refseq sequences (Sigma).
Given the profound importance of the regulation of
gene expression by miRNAs in both normal and malig-
nant cells, the identiﬁcation of their speciﬁc targets is an
important objective for the functional analysis of the
genome. The strategy described in this study should
pave the way for the rapid identiﬁcation and validation
of large panels of miRNA targets. Combined with
next-generation sequencing this strategy allows
high-throughput, systematic identiﬁcation of targets of
speciﬁc miRNAs in a relatively short time.
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